Hepion pharmaceuticals to participate in 2023 cantor global healthcare conference

Edison, n.j., sept. 21, 2023 (globe newswire) -- hepion pharmaceuticals, inc. (nasdaq:hepa), a clinical stage biopharmaceutical company focused on artificial intelligence (“ai”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“nash”), fibrotic diseases, hepatocellular carcinoma (“hcc”), and other chronic diseases, today announced that its chief executive officer, robert foster, pharmd, phd, will participate in a panel discussion during the 2023 cantor global healthcare conference on wednesday, september 27, 2023 at 9:45 a.m. et in nyc.
HEPA Ratings Summary
HEPA Quant Ranking